In Acorda Therapeutics, Inc. v. Roxane
Laboratories, Inc., the Federal Circuit affirmed the
district court decision finding four Acorda Orange Book-listed
patents for Ampyra® invalid as obvious. Acorda raised a number
of arguments on appeal, but this article focuses on the impact of a
blocking patent on consideration of objective indicia of
non-obviousness.
The Acorda Ampyra® Patents At Issue
Ampyra® (4-aminopurine sustained release tablets) is
approved for improving walking in patients with multiple sclerosis
(MS). The Orange Book-listed patents for Ampyra® include the
four Acorda patents at issue in this case—U.S. Patent Nos.
8,00,826, 8,663,685, 8,354,437, and 8,440,703—and an earlier
patent licensed from Elan, U.S. Patent No. 5,540,938.